fbpx

molecules of the month

June 2022

A SETD2 inhibitor with Fast Track Status for hematological malignancies, a CNS-penetrating, ATP-competitive LRRK2 inhibitor for Parkinson’s disease, and an oral nonsteroidal mineralocorticoid receptor antagonist are some examples of this month's MOTM.

In the slide deck, you'll find a small molecule that modulates a protein that has only been targeted with antibodies so far and a drug that takes advantage of the glutamate NMDA receptor hypofunction hypothesis.

Check out the ten molecule minireviews in the slide deck, which covers:

  • Where are all of the Molecules of the Month in clinical development?
  • What's known about differentiation from previous molecules?
  • Where did the starting points come from?
  • Industry context, mechanism of action details, and more…

Thanks to reviewers Bryan McKibben, PhD and Chris Gampe, PhD for their nominations and commentary this month.

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.
Newsletter

nominate a molecule

Encountered an interesting new molecule? Let your community know!

become a reviewer

Get sneak previews of upcoming molecules and share your knowledge and expertise with the drug discovery community.

Molecules

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.
Newsletter

Join Subscribers from

…and hundreds more!